Program
Candidate UTI vaccine low dose formulation 1
Also written as “Candidate UTI vaccine low dose formulation 2”, “Candidate UTI vaccine medium dose formulation 1” and “Candidate UTI vaccine medium dose formulation 2”.
Its studies are mostly in Urinary Tract Infections, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | May 31, 2027phase 2 · NCT06702449 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2024First study: phase 2 study in Urinary Tract InfectionsFirst studyNCT06702449 · 448 planned · United States, South Africa
Ahead
- May 31, 2027Primary completion: phase 2 study in Urinary Tract InfectionsNCT06702449
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Candidate UTI vaccine low dose formulation 1”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06702449Urinary Tract Infections · United States, South Africa | 2 | Recruiting | May 31, 2027 | 448 |
How it is read
Names in the registry
- “Candidate UTI vaccine low dose formulation 1”, 1 entry
- “Candidate UTI vaccine low dose formulation 2”, 1 entry
- “Candidate UTI vaccine medium dose formulation 1”, 1 entry
- “Candidate UTI vaccine medium dose formulation 2”, 1 entry
- “Candidate UTI vaccine high dose formulation 1”, 1 entry
Conditions, from the studies’ own filings
- Urinary Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.